Suppr超能文献

相似文献

1
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.
AAPS J. 2013 Apr;15(2):551-8. doi: 10.1208/s12248-013-9464-8. Epub 2013 Feb 14.
3
On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):195-209. doi: 10.1111/j.1742-7843.2009.00513.x. Epub 2009 Dec 29.
6
Translational strategies for development of monoclonal antibodies from discovery to the clinic.
Drug Discov Today. 2009 Mar;14(5-6):298-305. doi: 10.1016/j.drudis.2008.12.008. Epub 2009 Jan 17.
7
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
AAPS J. 2015 Mar;17(2):389-99. doi: 10.1208/s12248-014-9690-8. Epub 2014 Dec 3.
9
Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.
CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):5-15. doi: 10.1002/psp4.12245. Epub 2017 Nov 23.
10
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):73-85. doi: 10.1016/j.vascn.2014.05.004. Epub 2014 May 28.

引用本文的文献

1
Human FcRn Tissue Expression Profile and Half-Life in PBMCs.
Biomolecules. 2019 Aug 15;9(8):373. doi: 10.3390/biom9080373.
2
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
Protein Cell. 2018 Jan;9(1):15-32. doi: 10.1007/s13238-017-0408-4. Epub 2017 Apr 19.
3
Drug Design and Discovery: Principles and Applications.
Molecules. 2017 Feb 13;22(2):279. doi: 10.3390/molecules22020279.
4
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.
AAPS J. 2015 Jul;17(4):828-36. doi: 10.1208/s12248-015-9766-0. Epub 2015 May 2.
5
Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment.
J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):141-51. doi: 10.1007/s10928-014-9352-6. Epub 2014 Mar 12.

本文引用的文献

1
A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.
3
Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.
J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):769-86. doi: 10.1007/s10928-011-9219-z. Epub 2011 Oct 16.
4
Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.
Future Med Chem. 2009 Nov;1(8):1371-4. doi: 10.4155/fmc.09.124.
5
Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.
Curr Top Med Chem. 2011;11(4):404-18. doi: 10.2174/156802611794480864.
6
2010 FDA drug approvals.
Nat Rev Drug Discov. 2011 Feb;10(2):82-5. doi: 10.1038/nrd3370.
8
Therapeutic monoclonal antibody concentration monitoring: free or total?
Bioanalysis. 2010 Jun;2(6):1125-40. doi: 10.4155/bio.10.64.
9
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
MAbs. 2011 Jan-Feb;3(1):61-6. doi: 10.4161/mabs.3.1.13799. Epub 2011 Jan 1.
10
The challenge of selecting the 'right' in vivo oncology pharmacology model.
Curr Opin Pharmacol. 2010 Aug;10(4):391-6. doi: 10.1016/j.coph.2010.06.012. Epub 2010 Jul 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验